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ABSTRACT 
 
TITLE OF THE ABSTRACT     :      PREVALENCE OF HUMAN PAPILLOMA VIRUS IN                                                                   
                                                             LARYNGEAL CANCERS 
 
DEPARTMENT                       :       OTORHINOLARYNGOLOGY 
 
NAME OF THE CANDIDATE :      PHILIP GEORGE 
 
DEGREE AND SUBJECT        :       MS ENT 
 
NAME OF THE GUIDE          :      Dr. RAJIV MICHAEL 
 
OBJECTIVES                          :       To find out the prevalence of Human Papilloma virus in 
laryngeal cancers in the ENT Department of a tertiary level teaching hospital 
 
METHODS                              :      The study was conducted in the ENT outpatient 
department and in the ENT operating room at Christian Medical College,Vellore between 
November 2011 and July 2013. Study included 30 cases of laryngeal cancers and 30 controls 
which were benign lesions of vocal cords such as polyps,cysts or nodules.Cases and controls 
were evaluated in the ENT outpatient department and explained about the study in detail and 
were given an information sheet for clarifications. Informed valid consent was taken.Tissue 
was taken for the study when patient was posted for a direct 
laryngoscopic/microlaryngoscopic biopsy of the lesion. 
                                                             Tissue is taken for histopathological examination as 
well as HPV study.The tissue obtained is transferred to a VTM tube,i.e viral transport 
medium tube and is taken to the virology lab in an ice container. Viral transport medium is a 
balanced isotonic solution at physiological pH. It maintains the virus in the viable state.It 
contains fetal calf serum and antibiotics.                     
Once received in lab, the samples were transferred from the VTM tube to a 1.5ml eppendorf 
tube and stored at -80
0
C until  further testing   in  -80 degree freezer.The next step is DNA 
extraction using DNA extraction kit, DNeasy® Tissue kit: (Qiagen GmbH, Hilden, 
Germany). The extracted DNA undergoes Polymerase chain reaction.A known positive 
control was used for PCR and beta-globin serves as internal control.  
If sample was positive for HPV,sequencing is done to identify the genotype.The amplified 
PCR products were purified by Millipore filtration and sequenced directly using an ABI 
Prism Big Dye terminator cycle sequencing ready reaction kit. Finally, the data was analyzed 
using Bioedit software version 7.0.5.3 and study sequences compared to the GenBank HPV 
sequences. WHO recommended CHUV assay had to be used in case of 2 samples which were 
not able to be sequenced using routine methods 
From the previous studies in the literature the average prevalence of HPV in laryngeal 
 carcinoma is 25%. 
n=2pq(Zα + Zβ)2/(P1-Po)2 
By applying the formula n=73 
Hence,in each arm 73 cases should be studied. 
But the average number of microlaryngoscopy for cases  of laryngeal cancers in CMC is 3-4 
per month. Hence the aim was to study 30 cases and 30 controls. 
RESULTS                           : Out of the 30 cases of laryngeal squamous cell carcinoma 
cases,4 were positive for HPV whereas there were no positive HPV cases in the control 
group. One was HPV 16 type and another one HPV 11 type. Two other positive cases were 
not able to be sequenced probably due to low viral load. The results of HPV in laryngeal 
cancers were statistically insignificant with a p value of 0.052.Our study showed that both 
smoking and tobacco chewing had 5 times increased risk of acquiring laryngeal cancers.  
CONCLUSION             : As there were 4 HPV positive cases in the cancer group whereas 
there were none in the control group,there is more trend towards HPV positivity in the cancer 
group.Further studies are essential to prove the confirmatory role of HPV in laryngeal cancers 
HPV subtyping needs to be done for all juvenile and adult-onset laryngeal papillomatosis in 
view of chances of malignant transformation.These patients need to be followed up regularly. 
HPV testing should be made mandatory in the workup of laryngeal cancer patients especially 
in young patients without any co-existing risk habits such as smoking ,tobacco chewing and 
alcohol consumption. 
Key words:Human papilloma virus,laryngeal ancer 
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INTRODUCTION 
Laryngeal cancer is the most common head and neck cancer worldwide
4
. Squamous cell 
carcinoma is the most common type of tumour comprising 90 % or more of all laryngeal 
malignancies
94
.  
Various etiological factors have been described in laryngeal carcinogenesis. Tobacco and 
alcohol plays a major role in development of laryngeal cancers. Recently there is 
increased evidence that Human papilloma virus belonging to the family papillomaviridae 
is known to have a role in causing laryngeal cancers
1
. 
Human papilloma virus is known to cause cancers of oropharynx, cervix, vulva, penis and 
anus
2
.It also causes benign lesions like warts and papillomas.HPV 16 and 18 are the high 
risk types which commonly cause cancer
3
.HPV is known to have a synergestic action 
with other etiological agents more than an independent action.However the role of HPV 
needs to be closely studied in patients with laryngeal cancers without history of 
addictions. 
The classical location of HPV infection in the upper aerodigestive tract has been in the 
larynx in the form of juvenile and adult laryngeal papillomatosis.However recently there 
has been an overshadowing of HPV infection in larynx by its involvement in 
oropharyngeal cancers.Despite the low risk HPV 6 and 11 subtypes causing these 
papillomas there have been cases with malignant transformation
57
.  
This  proposed research scheme aims at finding out the prevalence of HPV in laryngeal 
cancers.The study design was a case-control study. Cases will be laryngeal cancer 
2 
 
patients and controls will be patients with vocal cord polyps or other benign conditions of 
vocal cords like nodules or cysts. 
As per the western literature the incidence of HPV subtypes in laryngeal carcinoma may 
be identified in upto 40% of cases
94
.
 
There is paucity of literature on the correlation 
between  HPV and laryngeal cancers in an Indian population
4
.Hence this study aims at 
finding the prevalence of Human papilloma virus in laryngeal cancers in India through a 
case control study. 
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AIMS & OBJECTIVES 
• Aim : To understand the role of HPV in the etiopathogenesis  and prognosis of laryngeal 
cancers  
• Objective : To find out the prevalence of Human Papilloma virus in laryngeal cancers in 
the ENT Department of a tertiary level teaching hospital 
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REVIEW OF LITERATURE 
The role of Human papilloma virus in head and neck cancers is being studied in detail in 
recent years .The role of high risk types of human papilloma virus in cervical 
carcinogenesis is well established. Recent  studies have revealed the  pivotal role of HPV 
in causing oropharyngeal cancers
5
.Further studies were aimed at detecting the  role of 
HPV in other head and neck sites mainly the  larynx. 
Cancer of the larynx is the second most common malignancy of the upper aerodigestive 
tract (UADT)
101
.This accounts for approximately 25% of all head and neck malignancies. 
Squamous cell carcinoma is the most common histological type accounting for 90%
6
 of 
cases. In India, laryngeal carcinoma constitutes 2.63% of all body cancers, ten times more 
common in males than females (4.79% vs 0.47%) with an incidence of 3.29 new cases in 
males and 0.42 new cases in females for one lakh population
100
. There seems to be a 
tendency for the laryngeal cancer to be mainly a disease of  middle aged men with a peak 
incidence in the seventh decade. Women are affected in a comparatively younger age 
with a peak incidence at less than sixty years
7
.  
Although a large variety of malignancies are reported in the larynx, 85-95 percentage of 
all laryngeal malignancies are squamous cell carcinoma (SCC), arising from the epithelial 
lining of the larynx
94
. First reports on HPV types in spontaneously arising laryngeal 
cancers(HPV 16 & 30) appeared in 1986(Kahn et al,1986;Scheurlen et al,1986)
8
  
Since then many studies have been looking into the role of Human papilloma virus in the 
aetiology of laryngeal cancers. 
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EMBRYOLOGY OF LARYNX 
The development of the larynx starts during the fourth week of embryonic 
development.The tracheobronchial diverticulum appears just below the hypobranchial 
eminence in the ventral wall of the primitive pharynx . An oesophagotracheal  septum is 
formed from the edges of the groove which fuses caudally,leaving a slit-like aperture 
cranially into the pharynx. The resulting tube is lined with endoderm from which the 
epithelial lining of the entire respiratory tract develops. The cranial end of the tube forms 
the larynx and trachea and the caudal end the bronchi and lungs. 
The larynx is subdivided into the supraglottis,the glottis and the subglottis. The 
buccopharyngeal primordium gives rise to the supraglottic larynx which develops from 
the third and fourth branchial arches. The glottis and subglottis are derived from the 
tracheobronchial primordium from the sixth branchial arch and are formed by the union 
of lateral furrows that develop on each side of the tracheobronchial primordium 
Arytenoid swellings appear on both sides of the traheobronchial 
diverticulum.Aryepiglottic folds are formed from the arytenoids swellings. The 
hypobranchial eminence becomes the epiglottis. The glottis forms just above the level of 
the primitive aperture. The thyroid cartilage develops from the  cartilages  of  the  fourth    
pharyngeal arch and the cricoid cartilage and the cartilages of the trachea develop from 
the sixth arch during the sixth week with the trachea increasing rapidly in length from the 
fifth week onwards. The mesoderm of each pharyngeal arch differentiates into cartilage, 
muscle and vascular structures of that arch.  
The supraglottis is supplied by the superior laryngeal arteries, and its lymphatics drain 
into deep cervical chain nodes at  levels II and III. The glottis and subglottis are supplied 
6 
 
by the inferior laryngeal arteries, and similarly, lymphatic drainage from these two 
regions follows these arteries to drain into prelaryngeal and pretracheal nodes (Level VI), 
before reaching the deep cervical chain nodes in level IV
9
.There is an increased chance of 
bilateral lymphatic metastases from supraglottic  carcinoma because the supraglottis is 
formed without a midline union and its lymphatics drain bilaterally
10
. 
                                       
 
Fig.1 EMBRYOLOGY OF LARYNX(Adopted from Review of MEDICAL 
EMBRYOLOGY Book by BEN PANSKY, Ph.D, M.D.) 
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ANATOMY OF THE LARYNX 
The larynx extends from the laryngeal inlet to the inferior border of the cricoid cartilage. 
Anatomically the  larynx is divided  into the supraglottis,glottis and subglottis by the false 
and true cords. The supraglottis consists of superiorly the epiglottis and aryepiglottic 
folds as they sweep down to the arytenoids. Its lower border is formed by the ventricular 
bands (false cords) which form the upper border of the glottis. The inferior surface of the 
glottis is a horizontal plane 1cm inferior to the inferior limit of the supraglottis
92
.The sub 
glottis becomes the trachea at the lower border of the cricoid.The framework of the larynx 
consists of the hyoid bone, paired and unpaired  cartilages connected by 
ligaments,membranes and intrinsic and extrinsic muscles to give it stability. It is lined 
with a mucous membrane that is continuous above with the pharynx and below with that 
of the trachea. 
 
 
Fig.2 Parts of larynx 
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Thyroid,cricoid and epiglottis are the unpaired cartilages and corniculate,cuneiform and 
arytenoids are the paired cartilages(Fig.4).The Thyroid cartilage has two alae which meet 
anteriorly forming an angle.  Vocal folds are attached to the middle of thyroid 
cartilage.The cricoid cartilage is the only cartilage forming a complete ring and has an 
expanded lamina posteriorly and a narrow arch anteriorly..The epiglottis is an elastic 
cartilage forming the anterior wall of the laryngeal inlet. It is divided  into suprahyoid and 
infrahyoid epiglottis by the hyoepiglottic ligament.The arytenoid cartilages are paired 
cartilages and posses a base,muscular process and a vocal process which gives 
attatchment to the voal cord.The corniculate cartilage articulates with the apex of 
arytenoid cartilage.The cuneiform cartilages are situated in the ayepiglottic folds and give 
support to it. 
 
                                         Fig.3  Normal larynx 
The muscles of the larynx are divided into extrinsic and intrinsic muscles.Extrinsic 
muscles attatch the  larynx to the neighbouring structures and maintain the position of 
larynx in the neck.Extrinsic muscles are divided into a suprahyoid and an infrahyoid 
groups. 
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The suprahyoid group consists of mylohyoid, geniohyoid, stylohyoid,digastrics 
,stylopharyngeus,  palatopharyngeus and salpingopharyngeus muscles.The infrahyoid 
group consists thyrohyoid,sternothyroid and sternohyoid muscles. The intrinsic muscles 
are all paired and move the cartilages in the larynx and regulate the mechanical properties 
of the larynx.They comprise  the posterior cricoarytenoid, lateral 
cricoarytenoid,transverse arytenoids,oblique  arytenoids, thyroarytenoid, cricohyroid, 
aryepiglotticus and thyroepiglottius muscles . 
The motor and sensory nerves of the larynx are derived from the vagus by way of its 
superior and recurrent laryngeal nerves. The arterial supply of the larynx is derived from 
laryngeal branches of the superior and inferior thyroid arteries and 
the cricothyroid branch of the superior thyroid artery.The lymphatic drainage of the 
larynx is divided into upper and lower drainage groups by the vocal folds. The larynx 
above the vocal folds is drained by vessels that accompany the superior laryngeal vein 
and pierce the thyrohyoid membrane emptying into the upper deep cervical lymph nodes. 
The larynx below the vocal folds drains to the lower deep cervical chain often through the 
prelaryngeal and pretracheal nodes.  
10 
 
 
Fig.4 External framework of larynx(adopted from the book Clinical Anatomy by Harold 
Ellis) 
Histology of larynx 
The mucous membrane lining of the larynx is closely attached over the posterior surface 
of the epiglottis, the cartilages and over the vocal ligament. Elsewhere, it is loosely 
attached and prone to oedema. Most of the larynx is lined by the respiratory type 
epithelium that is pseudo stratified ciliated columnar epithelium. The upper half of the 
posterior surface of the epiglottis, the upper part of the aryepiglottic fold, the posterior 
glottis and the vocal folds are covered with nonkeratinizing stratified squamous 
epithelium.Mucous glands are freely distributed throughout the mucous membranes and 
are particularly numerous on the posterior surface of the epiglottis where they form 
11 
 
indentations into the cartilage and in the margins of the lower part of the aryepiglottic 
folds and in the saccules. The vocal folds do not possess any glands 
 
                                                 Fig.5 Histology of larynx 
Vocal fold polyps 
A true vocal polyp is a benign swelling of greater than 3 mm that arises from the free 
edge of the vocal fold . Vocal fold polyps are caused by inflammation caused by stress or 
irritation
11
.It is usually single, but can occasionally be seen on bilateral vocal cords. It is 
claimed that polyps are the most common structural abnormality that cause hoarseness 
and they affect men more than women. They are most frequently seen in smokers and 
between the ages of 30 and 50 years
12
.Voice misuse is an important etiological factor for 
polyp formation.Certain patients may develop polyp after yelling or shouting usually 
12 
 
when the vocal folds are already inflamed due to laryngitis and gastroesophageal reflux. 
There will be disruption to the vascular basement membrane, proliferation of capillaries, 
thrombosis, minute haemorrhage and exudation of fibrin.
15
 Vocal fold polyps are 
typically caused by acute and chronic trauma to the microvasculature of the superficial 
lamina propria 
14
 . Hyperfunctional glottal sound production causes shearing stresses 
which lead to bleeding into the SLP and malformed neo-vascularized masses.Some 
polyps have a haemorrhagic appearance whereas others are more gelatinous and 
grey.Speech therapy may provide the patient ease of symptoms,but is unlikely to result in 
resolution of the polyp.It is advisable to remove the  polyps under  general anaesthetia.
15
 
The aim is to restore the smooth edge of the vocal cord allowing them to close fully and 
vibrate normally. 
                                              
Fig.6 Right vocal cord polyp 
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Vocal fold nodules 
Vocal nodules are bilateral small swellings (less than 3mm in diameter) that develop on 
the free edge of the vocal fold at the mid membranous portion. Vocal cord nodules have 
various synonyms.The various synonyms are teachers' nodules, laryngeal nodules, , 
parsons' nodes laryngeal nodes, corditis nodosa, singers' nodes or  screamers' 
nodes
16
.Voice abuse is the commonest etiology of the lesions.Singers and teachers are 
more prone for this condition.Nodules are formed due to vascular disorders secondary to 
overstrain
17
.Speech therapy is the first line of treatment.Surgical techniques include 
microsurgical methods and laser excision
18
.                                
                        
                                         Fig.7 Bilateral vocal cord nodules                     
Vocal fold cysts 
Vocal fold cysts (VFC) may be within the sub epithelium or in the ligament. It is usually 
unilateral. Significant reduction in vibratory function of the mucosa is noted in 
stroboscopy. Vocal fold cysts do not resolve with voice therapy. Microlaryngoscopic 
surgery is needed and it is confirmed intra operatively by the presence of an encapsulated 
14 
 
lesion.                     
  
Fig.8 Right Vocal cord cyst 
ETIOLOGY OF CARCINOMA LARYNX 
The most common head and neck cancer is laryngeal carcinoma .It is well known that the 
development of laryngeal cancer is influenced by environmental and life style factors like 
tobacco use and alcohol consumption
19
.Other factors which lead to development of 
laryngeal cancers are exposure to toxins,human papilloma viruses,exposure to 
radiation,dietary factors and laryngopharyngeal reflux
20
.Human papilloma virus acts as a 
co-adjuvant  in the formation of  laryngeal cancers along with other factors like tobacco 
use and alcohol consumption.HPV has a synergestic action rather than action alone
21
.In 
people without habits of tobacco use and    alcohol consumption,bile reflux and exposure 
to human papilloma virus are considered to have a significant contribution. High risk 
types of  HPV 16 and 18 have been found to have role in laryngeal carcinoma
96
. 
 
15 
 
 Tobacco and alcohol 
The main causative agent in laryngeal cancer has been identified as tobacco 
smoking
4
.The risk is proportional to the intensity and duration of tobacco or alcohol 
consumption, and the risk decreases slowly after cessation but does not return to the 
baseline rate for at least 20 years. The risk varies with the type of tobacco exposure (e.g., 
cigar vs. cigarette, filtered vs. Non filtered cigarettes), But the most important factors are 
the amount of tobacco consumed and the duration of exposure. Processed tobacco 
contains at least 30 known carcinogens. Tobacco smoke contains a high concentration of 
reactive oxygen species and more than 50 known carcinogens and procarcinogens.
22
                                                                                      
Increased consumption of alcohol and tobacco has a multiplicative effect in causing 
laryngeal cancers
23
-
24
.  Stable mutations can be caused by the DNA lesions induced by 
tobacco smoke carcinogens. Initiation of carcinogenesis is by oncogenes and tumor 
suppressor genes. At the same time, cells provide self-protection processes by carcinogen 
detoxication, DNA repair and apoptosis.There occurs competition between the cell 
protection processes and the mutation pocessses
25
.A metanalysis of 14 studies on effects 
of tobacco and alcohol in aerodigestive cancers by Zeka A et al, tobacco appeared to have 
a much stronger effect on the larynx than on any of the other aerodigestive sites.Alcohol's 
effect was strongest on the pharynx.The study confirmed the multiplicative effects of 
tobacco and alcohol
26
. Significant dose-response trends for  tobacco use were observed 
for both supraglottic and glottic cancers, with a potentially  more important effect for 
supraglottic cancer.The frequency and duration of the tobacco use were the significant 
factors
27
.Every incremental increase in pack years of smoking increases the risk of 
laryngeal cancers, likewise ―heavy‖ drinkers are more prone than  ―social‖ drinkers19. 
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Reflux disease and laryngeal carcinoma 
The relation between Gastroesophageal reflux disease (GERD) and upper aerodigestive 
tract carcinoma was initially suggested by Gabriel and Jones in 1976
28
.There is 
controversial evidence regarding relation between gastroesophageal reflux disease and 
laryngeal carcinoma
29
. The effect of reflux disease is demonstrated more clearly in 
studies involving laryngeal cancer patients who were non smokers.In a retrospective 
study by  Morrison on laryngeal cancers,
 
he  noted that 47% of lifelong non-smokers had 
GERD signs and symptoms
30
.Similarly, in a study by Mercante et al,he  found that 25% 
of nonsmoking cancer subjects had GERD, whereas only 5% of nonsmoking control 
subjects had GERD
31
.The metaanalysis by Mohammed et al  concluded that GERD is two 
times more common in laryngeal subjects than in control population
29
. Epithelial growth 
factor receptor(EGFR) role in laryngeal squamous cell carcinomas have already been 
studied.Increased expression of EGF has been seen in response to the bile reflux on the 
esophageal epithelial cells and similar effect maybe expected in laryngeal mucosa as 
well
32
. The greater distance between the laryngeal mucosa and the direct origin of gastric 
acid increases the time limit(>20 years) for the development of damaging action
33
. 
Occupation and laryngeal cancers 
In a study by Paget-Bailley et al,99 publications relating to occupational exposure and 
laryngeal cancers were analysed.Exposure to  polycyclic aromatic hydrocarbons , engine 
exhaust, textile dust, and working in the rubber industry  were found to have increased 
meta-relative risk. No significant association was noted with exposures to wood dust, 
formaldehyde, and cement dust
34
.Increased incidence of laryngeal squamous cell 
17 
 
carcinoma is seen in nickel and chromate refining workers
35
.There is probable association 
between asbestos and laryngeal cancers
36
. 
Diet and laryngeal carcinoma 
There is an increased risk for laryngeal carcinoma with low intake of fruits and 
vegetables.Low intake of vitamin C, beta-carotene and vitamin E were also associated 
with increase risk for laryngeal cancers
37
.Direct association with laryngeal cancers were 
noted with animal products  and the animal unsaturated fatty acids .Vegetable unsaturated 
fatty acids and the starch-rich patterns did not show any significant laryngeal cancer 
risk
38
. 
Laryngeal Cancer and genetics 
Mutations maybe produced by activation of proto-oncogenes and inactivation of tumour 
suppressor genes.The cell turnover  is maintained by an equilibrium between growth 
promoting and growth restraining signal transduction and the natural cell loss.Mutations 
occur  in the form of deletions, rearrangements, point mutations, translocations or 
reduplications.Aggregation of these  genetic alterations give rise to multistep 
carcinogenesis
39
. 
Familial predisposition and laryngeal cancers 
Incidence of  upper aerodigestive tract cancers is higher in first degree relatives of head 
and neck cancer patients as compared to cancer free controls
90
.The intermediate 
metabolites formed in an attempt to detoxify the carcinogens are more carcinogenic than 
the carcinogens itself.An efficient enzyme system is essential to detoxify the danger 
18 
 
compounds.Glutathione S-transferase and N-acetyltransferase 1 are important enzymes in 
this context. Acetylating action of  variety of carcinogenic aromatic amines is done by N-
acetyltransferase 1.A Japenese study on a series of  oral squamous cell carcinomas 
revealed increased risk for people with a particular  polymorphism of N-
acetyltransferase1
91
.  
GST family consists GST α,µ (M), π (P) and θ (T).Polymorphism in several members of 
the GST family has been analysed in HNSCC. GSTMI AB genotype may be associated 
with a lower risk for all HNSCC.GSTM3 BB genotype is specifically associated with 
lower risk of laryngeal cancers.GSTP 1 AA genotype is specifically associated with a 
lower risk of oral/pharyngeal cancers
40
.Lack of GSTMI gene in induvidals  have been 
shown to be at an increased risk for all types of HNSCC
41
. 
Molecular biology of laryngeal cancers 
The molecular biology of laryngeal squamous cell carcinoma is a complex system and no 
single entity is responsible for carcinogenesis.The characteristic features of cancer are 
increased cell proliferation and decreased cell death.This is brought about by inactivation 
of tumour suppressor genes,activation of oncogenes or both.Progressive accumulation of 
genetic alterations  lead to selection of a clonal population of transformed cells and lead 
to cancer
42
.The precise number of genetic alterations needed before development of 
cancer is difficult to define.However Renan in 1993 put forth  a statistical model in which 
he suggested between six to ten genetic alterations have  to accumulate for 
carcinogenesis
43
. Knudson
 put forth his model of the ―two-hit‖ hypothesis in 1971. He 
described a model in which two copies of the parentally inherited Rb gene were 
inactivated either by mutation or by loss of chromosomal material, leading to 
19 
 
development of hereditary or sporadic retinoblastoma
44
 Califano and associates
 
used 
microsatellite analysis and  correlated allelic imbalance due to chromosomal loss and gain 
with varying grades of dysplasia in premalignant lesions.He defined the progression of 
normal mucosa to invasive carcinoma which is demonstrated by the following flowchart
39
 
                                                               Normal mucosa 
 
                                                                   Hyperplasia 
               
                                                                    Dysplasia 
                                                                
                                                                Carcinoma insitu 
                                                                
                                                              Invasive carcinoma 
                                                                   
                                                                   Metastasis 
There were clonal, genetic changes in even the earliest of lesions.The first genetic 
alterations to occur in the progression to cancer were loss at 9p21 or 3p and the 
20 
 
corresponding inactivation of p16 and p14/aRF and putative 3p tumour suppressor genes.  
The model demonstrates the increased abberations in chromosomes as we go from normal 
mucosa to invasive carcinoma.There is loss of 3p and 9p as hyperplasia progresses to the 
stage of dysplasia.Dysplasia is classified into mild,moderate and severe grades. 17p loss 
result in transformation from mild dysplasia to moderate dysplasia whereas  p53 
mutation, 11 q13 amplification cause severe dysplasia.Loss of 17p13, 3p25, 3p14, 8q, 13q 
14q cause progression of dysplasia into carcinoma insitu.Invasive carcinoma results from 
carcinoma insitu by amplification of  4q, 6p, 8p, 18q loss, 3q.Overexpression of matrix 
metalloproteinases MMP-2 and MMP-9 causes metastasis.There is overexpression of 
Epidermal growth factor(EGFr) seen in the first stage of hyperplasia of cells.  
The concept of field cancerization was described by Slaughter and colleagues.They 
recognized histopathologic changes in the epithelia surrounding the invasive tumours and 
increased incidence of second primary tumours. 
WHO Classification of laryngeal tumors 
WHO has classified laryngeal tumours based on the histology into non-neoplastic lesions, 
pre-malignant lesions and primary laryngeal malignancies
1
.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
Primary laryngeal malignancies were again subdivided into Epithelial,malignant salivary 
gland tumors,neuroendocrine tumors,malignant soft tissue tumors,malignant tumors of 
bone and cartilage,haematolymhoid tumors.The WHO classification of primary laryngeal 
malignancies is listed below. 
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Primary Laryngeal Malignancies  
   
 Epithelial  
       Squamous cell carcinoma (SCC)  
    Verrucous SCC 
    Spindle cell carcinoma 
    Adenoid SCC 
      Basaloid SCC 
      Clear cell carcinoma 
      Adenosquamous carcinoma 
      Giant cell carcinoma 
         Lymphoepithelial carcinoma 
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 Malignant salivary gland tumors  
       Adenocarcinoma 
       Acinic cell carcinoma 
       Mucoepidermoid carcinoma 
       Adenoid cystic carcinoma 
       Carcinoma ex pleomorphic adenoma 
       Epithelial-myoepithelial cell carcinoma 
       Salivary duct carcinoma 
 
   
 Neuroendocrine tumors  
        Carcinoid tumor 
        Atypical carcinoid tumor 
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        Small cell carcinoma 
        Malignant paraganglioma 
 
   
 Malignant soft tissue tumors  
       Fibrosarcoma 
       Malignant fibrous histiocytoma 
       Liposarcoma 
       Leiomyosarcoma 
       Rhabdomyosarcoma 
       Angiosarcoma 
       Kaposi's sarcoma 
       Malignant hemangiopericytoma 
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       Malignant nerve sheath tumor 
       Alveolar soft part sarcoma 
       Synovial sarcoma 
       Ewing's sarcoma 
 
   
 Malignant tumors of bone and cartilage  
         Chondrosarcoma 
         Osteosarcoma 
 
   
 Hematolymphoid tumors  
        Lymphoma 
        Extamedullary plasmacytoma 
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 Fig.9 Distribution of laryngeal squamous cell carcinoma 
Squamous Cell Carcinoma of the Larynx 
Among the malignant tumors of larynx,squamous cell carcinoma is the most common.It 
accounts for 85-95% of laryngeal cancers.Squamous cell carcinoma may be 
macroscopically exophytic or endophytic. Microscopically it  has ‗prickle‘cells and 
keratin whorls.The second most common malignancies among laryngeal cancers are 
lymphomas.      
1%
51%
32%
2%
1% 9%
4%
Laryngeal squamous cell carcinoma
anterior surface of epiglottis glottis
supraglottis subglottis
laryngeal cartilage larynx,NOS
overlapping lesions of larynx
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Fig.10 Squamous cell carcinoma microscopy 
Pathology of laryngeal squamous cell carcinoma 
The characteristic feature of squamous cell carcinoma is squamous differentiation.It is 
defined by the formation of keratin and/or the presence of intercellular bridges
45
. SCC is 
graded by its histologic appearance into three categories: well, moderately, and poorly 
differentiated. Well-differentiated SCC resembles normal squamous epithelium and 
contains basal-type cells and squamous cells with keratinization and intercellular bridges. 
The nuclei are hyperchromatic and irregular in size and shape (pleomorphic), and the 
nuclear-cytoplasmic ratio is reduced. Atypical mitoses are rare. Moderately differentiated 
SCC has less keratinization, more atypical mitoses, and more nuclear pleomorphism. 
Intercellular bridges are present. Poorly differentiated SCC has minimal keratinization, 
minimal intercellular bridges, and numerous atypical mitoses
87
.  
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The histologic grade has been reported as having prognostic value.However, grading is 
subjective, and sampling error may influence the grading pattern.SCC invades the 
underlying tissue by breaching the basement membrane.The pattern of invasion can be 
expansive when there is well defined margins or infiltrative when there is ill defined 
margins. SCC in situ is the term assigned to a lesion in which the entire thickness of the 
epithelium shows the cellular features of carcinoma without invasion of the underlying 
stroma. Microinvasive SCC refers to SCC in which limited tumor invasion is confined to 
the area just deep to the basement membrane. 
Necrotising sialometaplasia and pseudoepitheliomatous hyperplasia are two entities 
which needs to be distinguished from squamous cell carcinoma.Immunohistochemistry is 
used to differentiate from these entities
46
.  Epithelial markers such as cytokeratin and 
epithelial membrane antigen are expressed in squamous cell carcinoma. 
Clinical presentation and staging 
The symptoms of laryngeal SCC depend on the site from which the lesion 
arises.Acording to the site of origin the presenting symptoms vary. Supraglottic tumors 
may present with dysphonia,dysphagia, odynophagia,  otalgia, stridor, dyspnea, or 
hemoptysis. There is rich lymphatic supply for the supraglottis.Hence patients with 
supraglottic SCC may also present with metastatic cervical adenopathy, without obvious 
laryngeal symptoms. Supraglottic SCC usually metastasizes to levels II, III, and IV. 
Levels I and V are involved by metastases rarely and only when other nodal levels are 
also involved
88
. 
The cardinal symptom of glottic SCC is hoarseness of voice which develops early in the 
natural history of the disease as the normal vibratory characteristics of the vocal cord are 
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altered by even a small lesion. Therefore patients with glottic SCC usually present with 
earlier stages of disease
47
. Glottic tumors remain localized in the glottis for prolonged 
periods, owing to the natural barriers to tumor spread (ligaments, membranes, and 
cartilages) and to the relative paucity of glottic lymphatics.If the early symptoms are 
ignored or attributed to other diagnoses, symptoms of advanced disease such as dyspnea 
and stridor may arise.SCC of the subglottis often presents with advanced-stage 
disease.Dyspnea and stridor are the most common symptoms of subglottic SCC. Because 
their onset is usually gradual and insidious, subglottic SCC may be misdiagnosed as 
asthma or other pulmonary diseases. 
Distant metastases from laryngeal SCC include not only hematogenous metastases to 
distant organs, but also lymphatic metastases to nodal groups outside the neck.The most 
common site for distant hematogenous metastases is the lung. The mediastinum is the 
most common site for distant lymphatic metastases
89
.The liver and skeletal system (ribs, 
vertebrae, and skull) are affected less often.  
TNM staging of laryngeal cancers 
Supraglottis 
T1 Tumor limited to one subsite of supraglottis with normal vocal cord mobility  
T2 Tumor invades mucosa of more than one adjacent subsite of supraglottis or glottis or 
region outside the supraglottis (e.g., mucosa of base of tongue, vallecula, medial wall of 
pyriform sinus) without fixation of the larynx  
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T3 Tumor limited to larynx with vocal cord fixation and/or invades any of the following: 
postcricoid area, pre-epiglottic tissues, paraglottic space, and/or minor thyroid cartilage 
erosion (e.g., inner cortex)  
T4a Tumor invades through the thyroid cartilage and/or invades tissues beyond the larynx 
(e.g., trachea, soft tissues of neck including deep extrinsic muscle of the tongue, strap 
muscles, thyroid, or esophagus) 
T4b Tumor invades prevertebral space, encases carotid artery, or invades mediastinal 
structures  
Glottis 
T1 - Tumour limited to vocal cord(s) (may involve anterior and posterior commissure) 
with normal mobility.  
T1a – Tumour limited to one vocal cord. (Fig.11) 
T1b – Tumour involves both vocal cords  
T2 – Tumour involves supra glottis and / or subglottis and /or with impaired vocal cord 
mobility  
T3 – Tumour limited to larynx with vocal cord fixation and/or invades paraglottic space 
and / or minor thyroid cartilage erosion.  
T4a – Tumour invades through thyroid cartilage and / or invades tissue beyond the larynx 
(eg: trachea, soft tissues of neck including deep extrinsic muscles of the tongue, strap  
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muscles, thyroid or oesophagus)  
T4b – Tumour invades pre vertebral space, encases carotid artery or invades mediastinal 
structures  
Subglottis 
T1 Tumor limited to the subglottis  
T2 Tumor extends to vocal cord(s) with normal or impaired mobility  
T3 Tumor limited to larynx with vocal cord fixation  
T4a Tumor invades cricoid or thyroid cartilage and/or invades tissues beyond the larynx 
(e.g., trachea, soft tissues of neck including deep extrinsic muscles of the tongue, strap 
muscles, thyroid, or esophagus)  
T4b Tumor invades prevertebral space, encases carotid artery, or invades mediastinal 
structures 
Regional lymph nodal staging 
NX Regional lymph nodes cannot be assessed. 
N0 There is no regional nodes metastasis. 
N1 Metastasis is in a single ipsilateral lymph node, 3 cm or less in greatest dimension. 
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N2 Metastasis is in a single ipsilateral lymph node, more than 3 cm but not more than 6 
cm in greatest dimension; or metastasis 
is in multiple ipsilateral lymph nodes, none more that 6 cm in greatest dimension; or 
metastasis is in bilateral or contralateral lymph nodes, none greater than 6 cm in greatest 
dimension. 
N2a Metastasis is in a single ipsilateral lymph node, more than 3 cm but not more than 6 
cm in greatest dimension. 
N2b Metastasis is in multiple ipsilateral lymph nodes, none more that 6 cm in greatest 
dimension. 
N2c Metastasis is in bilateral or contralateral lymph nodes, none more than 6 cm in 
greatest dimension. 
N3 Metastasis is in a lymph node more than 6 cm in greatest dimension. 
Distant Metastasis (M) 
MX Distant metastasis cannot be assessed. 
M0 There is no distant metastasis. 
M1 There is distant metastasis. 
 
Stage  T  N  M  
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Stage  T  N  M  
0 Tis- N0 M0 
I T1 N0 M0 
II T2 N0 M0 
III T3 N0 M0 
T1 N1 M0 
T2 N1 M0 
T3 N1 M0 
IVA T4a N0 M0 
T4a N1 M0 
T1 N2 M0 
T2 N2 M0 
T3 N2 M0 
T4a N2 M0 
IVB T4b Any N M0 
Any T N3 M0 
IVC Any T Any N M1 
Adopted from AJCC: Laryngeal. In: Edge SB, Byrd DR, Compton CC, et al., eds.: AJCC 
Cancer Staging Manual. 7th ed. New York, NY: Springer, 2010, pp 57-67. 
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                                               Fig.11 T1a glottic carcinoma 
Prognosis and prognosis predictors in laryngeal cancers 
The prognosis of laryngeal cancer patients depends on disease factors and patient 
factors.The 5 years survival rate is 64%, the rate for individual sites being  47% for 
supraglottic SCC, 79% for glottic SCC, and 30%-50% for subglottic SCC
48
.Clinical 
staging of the disease is an important prognosis predictor of the disease.In TNM 
staging,with increase in T and N,the prognosis becomes poor.N value is more important 
factor than T value
49
.The histological grading pattern,invasion pattern and peineural or 
vascular invasion may influence the survival and locoregional control
50
.Epidermal growth 
factor overexpression predicts chemosensitivity and radiosensitivity.Disease free survival 
is predicted by overexpression of cyclin D1/D2.Overexpression of both has the worst 
prognosis
51
.In a metaanalysis conducted for HPV in head and neck cancer,HPV related 
oropharyngeal cancers had a better prognosis compared to non HPV types
52
. 
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Human papilloma virus 
Papilloma viruses are icosahedral non-enveloped viral particles belonging to the 
taxonomic family papillomaviridae. They are DNA viruses.It has a circular double 
stranded DNA molecule of approximately 8 kb. The number of HPV types identified has 
reached 96 and will soon exceed 100.The first PV types were isolated about 30 years 
ago.
53
They are divided into high risk types,intermediate type and low risk types according 
to cervical carcinogenesis.
2
 All open reading frame (ORF) protein-coding sequences are 
restricted to one strand. 
Functionally,the genome is divided into three regions 
54
(Fig.12) 
(1)A non-coding upstream regulatory region of 400 to 1,000 bp, which is known as 
noncoding region or the long control region (LCR), or the upper regulatory region. 
This region contains the p97 core promoter along with enhancer and silencer sequences 
that regulate DNA replication by controlling the transcription of the ORFs. (2) The 
second is an early region consisting of ORFs E1,E2, E4, E5, E6, and E7, which are 
involved in viral replication.(3) third is a late region, which encodes the L1 and L2 
structural proteins for the viral capsid. 
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Fig.12 HPV genome 
E1 to E7 are seven early open reading frames which encode proteins involved in DNA 
replication, transcription, and cellular transformation.L1 and L2,the capsid proteins  are 
encoded by late open reading frames.Early genes E1 and E2 are expressed as proteins that 
bind to DNA and act as transcriptional activators or repressors, thus regulating virus 
transcription and genome replication. The E4 gene  is involved in maturation and release 
of papillomavirus particles and is expressed relatively late in virus replication.E6 and E7 
are described as viral oncogenes.They encodes proteins which bind to the tumour 
suppressor proteins. E6  induces  degradation of tumor suppressor protein p53 by 
encoding a protein that binds to it. E7 encodes a protein that binds to retinoblastoma 
protein(Rb) 
87
. Long control region (LCR) is the non-coding region which contains 
regulatory sequences that respond to steroid receptor hormones.
55
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Fig.13 Geographical distribution of HPV virus
56
 
HPV 16 and 18 together account for nearly 70% of cases of cervical cancer worldwide, 
but the relative distribution may vary according to ethnic and regional conditions. In Asia 
the third most frequent type is HPV 58 and then HPV 52
3
(Fig.13). 
HPV is an epitheliotrophic virus of almost 8000 base pairs.They are organized in early 
(E) and late (L) transcriptional genes. HPV is an obligatory intranuclear virus.The 
infection can access basal and parabasal cells in 3 different sites: at the site of mucosal 
injury, metaplastic epithelium, or the squamocolumnar junction.
57
 An HPV genotype is 
defined as a distinct one when the nucleotide sequence of its L, E6, and E7 genes differs 
from that of any other by at least 10%.pRb  causes  cell cycle arrest in mid to late G 1 
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phase where it is underphosphorylated by negative regulation of cell proliferation.
58
. 
Wild-type p53 acts as a cell cycle checkpoint after DNA damage.It induces  G 1 arrest or 
apoptosis and  maintain genomic stability. 
The papillomaviruses were originally clumped together with the polyomaviruses in one 
family, the Papovaviridae. This was because both groups had nonenveloped capsids and 
the common circular double-stranded DNA genomes. But  it was later recognized that the 
two virus groups have different genome sizes,  genome organizations, and no major 
nucleotide or amino acid sequence similarities.Hence the International Committee on the 
Taxonomy of Viruses (ICTV) have now officially recognized them as two separate 
families, Papillomaviridae and Polyomaviridae. The L1 ORF is the most conserved gene 
within the genome.This gene has therefore been used for the identification of new PV 
types.For a new PV isolate to be recognized,the complete genome has to be cloned and 
the DNA sequence of the L1 ORF should differ  by more than 10% from the closest 
known PV type. Differences between 2% and 10% homology define a subtype and a 
variant described by less than 2 %. This definition was agreed upon between all PV 
scientists working on PV taxonomy and diagnosis at the International Papillomavirus 
Workshop held in Quebec in 1995.The genus of papillomavirus contain alpha-,beta-
,gamma-,delta-,epsilon-,zeta-,eta-,thota-,lota-,kappa-,lambda-,mu-,nu-,xi-,pi-papilloma 
viruses.
3
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Fig.14 Human papilloma virus, under electron microscope(Adopted from National 
Institutes of Health) 
Infections caused by HPV virus Benign lesions 
Human papilloma virus is the causative organism for a wide range of diseases starting 
from common warts to head and neck squamous cell carcinoma and cervical 
carcinomas.HPV are known to cause laryngeal papillomas, anogenital condylomas,  skin 
cancer in patients with  
epidermodysplasia verruciformis
59
 and anal cancer. Type 1, 2, and 4 are associated with 
common warts and plantar  warts. Human papilloma virus associated with flat warts are 
Types 3, 10, 28, and 41. Types 5, 8,9, 12, 14, 15, 17, 19-25, 36, 46, and 47 are found in 
are epidermodysplasia verruciformis (EV) .Veneral warts or condyloma acuminate(CA) 
are caused by low risk type HPV 6 and HPV 11
60
. 
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Laryngeal papillomatosis is the most common benign neoplasm  of the larynx accounting 
for 84% of benign tumours
61
(Fig.15).It was first described by Morrell Mackenzie in 
1880.The condition is more frequently seen in children and is clinically divided into 
juvenile and adult onset laryngeal papillomatosis.Rarely,there can be malignant 
transformation for the papilloma lesions.It is seen in 3-7% of cases
62
Laryngeal 
papillomatosis is notorious for its recurrence.HPV 6 and HPV 11 are the most common 
causative organism for laryngeal papillomatosis eventhough other types have also been 
implicated.Most studies  reveal HPV 11 disease to be more aggressive than HPV 6
63
.The 
means of transmission in children is believed to be from mother‘s HPV infected genital 
tract and in adults through orogenital spread
64
,
65
.Hoarseness is the most common 
symptom at presentation because vocal folds are the first and predominant site of 
papilloma.The child's voice may be described as hoarse or weak from the time of birth. 
Stridor is often the second clinical symptom to develop, beginning as an inspiratory noise 
and becoming biphasic with progression of the disease. Other presenting symptoms 
maybe less commonly, chronic cough, recurrent pneumonia, failure to thrive, dyspnoea, 
dysphagia, or acute life-threatening events may be the presenting symptoms. After 
presentation, the disease may undergo spontaneous remission or persist in a stable state 
requiring only periodic surgical treatment. At the other extreme, RRP may become 
extremely aggressive, requiring frequent surgical treatment prompting early institution of 
medical adjuvant therapy. The adjuvant treatment modalities are antiviral 
therapy,photodynamic therapy,anti reflux therapy,indole-3-carbinol,retinoids and 
celecoxib
66
.Antiviral therapy include alpha-interferon
67
,ribavarin,cidofovir and acyclovir. 
Malignant degeneration is a rare but fatal transformation.About twenty pediatric cases 
with malignant transformation have been reported.Radiating the papillomas increase the 
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risk of malignant transformation.Adult onset laryngeal papillomatosis is commonly seen 
in young patients in the age group of 18-39 years. 
 
                                      Fig.15 Laryngeal papillomatosis 
HPV and oropharyngeal cancers 
The oropharynx was the first head and neck site found to be related to HPV related 
cancer.The cryptic epithelium of the tonsil and tongue base acts as  a reservoir for HPV 
and acts similar to the action in cervical carcinogenesis
68
.The viral reservoir provides 
increased access to the basal epithelial layer.In developed countries,HPV now contribute 
to 45%-90% of oropharyngeal squamous cell carcinoma cases
69
.Recent studies reveal 
oropharyngeal cancers,more specifically those of tonsils and base of tongue are associated 
with high risk human papilloma virus infection
70
.In a multinational study conducted by 
the International Agency for Research on Cancer (IARC), only 18% of oropharyngeal 
tumors were HPV positive
71
,Incidence rates for HPV related oropharyngeal cancers are 
higher in men than in women and oral sex has been the principal risk factor for such 
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cancers
72
.As in other  HPV associated cancers,HPV 16 is the commonly detected 
genotype
73
. 
The clinical presentation of HPV related OPSCC cases are a little different from that of 
non HPV related cases.HPV related cases are usually young,without a history of 
addictions like alcohol or tobacco. They are usually married and college educated and 
more commonly white
74
.Factors which increase the exposure to HPV such as number of 
oral or vaginal sexual partners,increase in age and infrequent use of barriers
5
. 
As only high risk types are responsible for the OPSCC,there is role for vaccination in 
these cancers.Vaccines promote neutralising antibodies that prevent the entry of virion 
particles.It do not halt the progression of existing lesions.Hence vaccination is only 
effective before the infection is established
75
. 
 Patients with OPSCC often have TNM staging with a high N and low T
76
. Poorly 
differentiated, nonkeratinizing, and with basaloid morphology is the usual histological 
finding
68
. 
The rate of progression and chances of locoregional spread were lower among HPV 
related than  non HPV related cases.The former had better survival rates compared with 
non-HPV related cases
68
.In a systematic review and metanalysis was conducted to study 
HPV in orophaaryngeal and non-oropharyngeal cancers by Mehanna etal.The study 
concluded increase in HPV positive cases over the last decade in Europe compared to 
North America.Non oropharyngeal cancers showed an overall prevalence of  21%.Non 
oropharyngeal cancers also showed a declining non-significant trend in HPV relation
77
. 
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HPV and cervical cancer 
Cervical cancer is the second most common cancer in women worldwide
75
.In early 1980s 
Harold zur Hausen, a German virologist first demonstrated the link between HPV and 
cervical cancer.He was awarded Nobel prize in Medicine or physiology in 2008 for his 
discovery.World Health Association, along with the European Research Organization on 
Genital Infection and Neoplasia and the National Institutes of Health Consensus 
Conference on Cervical Cancer, recognized HPV as an important cause of cervical cancer 
in 1996.HPV 16 and 18 are the most common genotypes causing cervical cancers.Other 
common types are 31 and 45
54
.The tools used in the screening and the diagnosis of 
cervical neoplastic lesions are papanicolaou testing (Pap smear) and HPV DNA testing
4
.A 
high HPV-DNA background prevalence, combined  with  an early age at sexual initiation, 
high number of partners of both men and women, and an important frequency of sexual 
contacts with prostitutes increases the incidence rate of cervical cancer for a given 
population . Other risk factors for cervical cancer are oral contraceptives, smoking, other 
sexually transmitted diseases, poor hygiene, and cervical inflammation
78
.Strong relation 
between human papilloma virus and cervical cancer along with the knowledge about the 
natural history of the virus has led to the development of prophylactic vaccines for 
cervical cancers
79
.Human papillomavirus L1 self assembling like particles are the 
contents of these vaccines.They induce strong neutralising antibody like action against 
papillomavirus infection.These antibodies block the virions from entering the basal layer 
of the epithelial cells
80
.Two vaccines are available the quadrivalent vaccine (Merck, 
Whitehouse Station, NJ  
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USA) and the bivalent vaccine (GlaxoSmithKline, Rixensart, Belgium).The quadrivalent 
vaccine contains virus-like particles to human papillomavirus types 6, 11, 16, and 
18.Bivalent vaccine contains virus-like particles to human papillomavirus types 16 and 
18.The quadrivalent vaccine is marketed as Gardasil by Merck,USA and the bivalent 
vaccine is marketed as Cervarix by GlaxoSmithKline,Belgium
79
(Fig.16). 
 
Fig.16 HPV Vaccines 
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These HPV vaccines have prophylactic action only and not therapeutic action.They are 
not effective in an existing disease but prevents the disease
81
. It is important to generate 
cell mediated immunity against HPV infected cells to control of cervical cancer and treat 
established HPV infections.It is possible only by development of therapeutic 
vaccines.Two early proteins of HPV, E6 and E7 oncoproteins, are the preferred targets 
because they are consistently expressed in virtually all cervical cancer cells and are 
necessary for the induction and maintenance of HPV-associated disease. Immune 
responses to these proteins are the basis of development of peptide-based 
vaccines
82
.Overlapping long peptides are the new area of interest in therapeutic 
vaccines.They can crossover the obstacle of MHC restriction which is a drawback of 
peptide vaccines.This is brought about by broadening the range of antigenic epitopes 
through inclusion of immunogenic peptides or peptides that direct CD4+ T-helper or 
CD8+ cytotoxic immune responses
83
. 
Other than cervical cancer,HPV is also known to cause cancer of the anus,vulva,penis and 
vagina.Current data shows HPV associated with 90%–93% of anal cancers,36%–40% of 
penile cancers, 40%–64% of vaginal cancers, and 40%–51% of vulvar cancers2. 
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The HPV proteins associated with cancer are E6 and E7 . There are six early (E1, E2, E3, 
E4, E6, and SE7) and two late (L1 and L2) proteins in the HPV genome.When a host cell 
is infected,two early proteins exons  E1 and E2 are expressed first.Early 6 and 7 proteins 
inactivate tumour suppressor proteins.E6 inactivate p53.E7 inactivate pRb.Expression of 
E6 and E7 is repressed by high levels of E2.Integration of host and HPV genome,disrupts 
E2 function.This prevents the repression of E6 and E7
2
. 
 Previous studies on HPV and laryngeal cancers 
In a study by Brandsma
93
 JL et al,6 patients of veruccous carcinoma of larynx were 
studied for HPV 16 type related sequences .They used the Southern and DNA dot blot 
hybridization for HPV DNA.All the 6 patients were positive  for HPV 16 type related 
sequences. 
In a study by Bauman
95
 et al,38 patients with laryngeal cancer were studied for presence 
of HPV DNA. HPV DNA was detected in 6  of the 38 lesions.HPV DNA was detected in 
16 % of cases. HPV types 16, 26, 31, 39,and 52, and p16 tumor suppressor protein 
expression was confirmed in 10 representative cases. 
In a study by Morshed K
96
, et al 3 groups were studied. Ninety three primary laryngeal 
squamous cell carcinoma (LSCC)tissue samples were collected. Forty nine specimens of 
normal mucosa were collected.The control group had 22 specimens of laryngeal nodules. 
Thirty three of the 93 samples from LSCC were positive for Human papillomavirus 
(35.5%). Four of 49 samples of the normal mucosa showed HPV(8.2 %).HPV was not 
detected in any of the sample from the control group. Twenty-eight of 33 (81.8%) were 
positive for HPV-16.6 of 33 (18.2%) were positive for HPV-18. 5 of 33 (15.1%) were 
positive for HPV-33. Multiple infections were also found. 5 of 33 (15.1%) showed 
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multiple infections. Three samples were positive for HPV-16 and HPV-33, 2 samples for 
HPV-16 and HPV-18. 
 Atula et al studied the  relationship between HPV infection and epithelial laryngeal 
malignancies. 27 laryngeal carcinoma cell lines from 22 patients were studied. Seven of 
27 (26%) cell lines and were found to harbour high-risk HPV. Seven of 12 (58%) tumour 
samples were found to harbour high-risk HPV. 
In a study by  Almadori 
98
et al the presence of HPV DNA was studied in 45 fresh 
squamous cell carcinoma (SCC) specimens and in 29 normal mucosa specimens collected 
from 45 primary laryngeal SCC patients.They used polymerase chain reaction.PCR with 
consensus primers that detect HPV types 6, 11, 16 and 18 were used.20 %,that is 9 out of  
45 patients were HPV positive.In normal laryngeal mucosa,in four of the 29 specimens 
(14%) ,the presence of HPV was  detected.  
In a study by Kreimer  et al,a prevalence of HPV DNA of  24 per cent of laryngeal 
squamous cell carcinomas was detected.   
Liu et al determined the prevalence and genotypes of HPV infection in laryngeal cancer 
specimens.84 specimens from pathologically confirmed LSCC patients were studied for 
the presence of viral DNA and possible virus integration into the cellular genome.  HPV 
L1 general primer amplification was used. HPV DNA was detected in 23 of the 84 LSCC 
samples,that is 27.4%. HPV16 were found in all 23 L1 positive samples. 
In a study by Gungor 
99
et al Human papilloma virus deoxyribonucleic acid was detected 
in seven of 95 cases of laryngeal squamous cell carcinoma,that is 7.36 per cent. 
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In a meta-analysis including 55 studies  addressing HPV prevalence and its association 
with laryngeal cancer the overall HPV prevalence in laryngeal cancer was found to be 
28.0% . HPV-16 was the most common subtype, with a prevalence of 19.8% . A 
significant association was found between HPV infection and laryngeal SCC risk, with a 
summary OR of 5.39
1
. 
In a study by Jacob et al, the prevalence of HPV infection in India was found to be 34 
percent of invasive laryngeal squamous cell carcinoma.Jacob et al studied the cellular 
manifestations of HPV in laryngeal cancers. The frequency of HPV infection in various 
neoplastic and non-neoplastic laryngeal tissues were investigated.The association of HPV 
with expression of  the tumor suppressor protein p53 and the proliferating cell nuclear 
antigen (PCNA) .The methods used were PCR for HPV detection and 
immunohistochemisty for expression of PCNA and p53.Six normal laryngeal tissues, 16 
laryngeal papillomas and 44 invasive  carcinoma tissues were studied. None among the 
normal laryngeal tissues showed the presence of HPV. Thirteen out of the 16 papillomas 
were positive for HPV and 15 (34%)out of the 44 invasive cancers were HPV 
positive.Significant correlation was noted between type of laryngeal neoplasm and p53 
accumulation  as well as presence of HPV and p53 accumulation  and PCNA expression 
indicating that HPV positive tumours showed significant p53 accumulation and increased 
proliferation. 
From the above studies the paucity of literature in the Indian scenario is well noted.As 
there is vast difference in the social ,religious and cultural backgrounds when compared 
to the West,it is important to have more local( Indian) studies on the relationship between 
HPV and laryngeal cancers.Hence this study is aimed at analysing the association 
between HPV and laryngeal cancers. 
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MATERIALS AND METHODS 
The purpose of the study is to find  the relation between human papilloma virus and 
laryngeal cancers.  
Type of study: Case control study 
Period of study: 2 years 
Setting: 
The study was conducted in the ENT outpatient department and in the ENT operating 
room at Christian Medical College,Vellore between November 2011 and July 2013. 
Cases and controls were evaluated in the ENT outpatient department and explained about 
the study in detail and were given an information sheet for clarifications. Informed valid 
consent was taken.Tissue was taken for the study when patient was posted for a direct 
laryngoscopic/microlaryngoscopic biopsy of the lesion. 
Dates of significance in the study are when patient is diagnosed clinically with carcinoma 
larynx,date of direct laryngoscopic/microlaryngoscopic  biopsy of the lesion which is 
done as part of standard protocol for confirmation of the diagnosis of laryngeal cancer.  
follow up of the result of the PCR analysis. 
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Eligibility criteria: 
1. Clinically diagnosed cases of carcinoma larynx based on clinical and flexible 
laryngoscopy examination. 
2. Control group will be patients with benign lesions of vocal cord like vocal cord 
polyps or  nodules. Cases and controls will be  1:1 ratio 
Exclusion criteria: 
1. Post Radiation therapy cases 
2. Recurrent cases of carcinoma 
3. Laryngeal papillomas 
Sample size calculation 
From the previous studies in the literature the average prevalence of HPV in laryngeal 
 carcinoma is 25% 
n=2pq(Zα + Zβ)2/(P1-Po)2 
P0=0.05 
P1=Po(OR/Po)/Po(OR-1)+1 
P=P1+Po/2 
q=1-p 
By applying the formula n=73 
Hence, in each arm 73 cases should be studied. 
But the average number of microlaryngoscopy for cases of laryngeal cancers in CMC is 
3-4 per month. Hence the aim was to study 30 cases and 30 controls. As there can be 
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inadequacy of tissue for PCR analysis in some patients,it was planned to study 40 cases 
and 40 controls. 
Method 
New clinically diagnosed cases and controls were recruited for the study. All clinically 
diagnosed cases of laryngeal malignancies underwent a flexible fibreoptic laryngoscopy 
in our outpatient department. The findings were carefully noted and extend of lesion, site 
and airway assessed. Patients with T2 and above lesions also underwent imaging– 
contrast enhanced computed tomography(CT) of the neck. Patients were explained about 
the study in detail and patient information sheet was given to the patient .Informed valid 
consent was obtained from patients who were willing to participate in the study. The 
proforma for the study was filled in the OPD and patient details were obtained. Patients 
participated from all the 3 units of our department .Patients were posted for 
microlaryngoscoy and biopsy of the lesion.   
MICROLARYNGO SCOPY-ENT OPERATING ROOM SETTING 
Patient is taken under general anaesthesia for microlaryngoscopy and biopsy of the 
lesion.The steps described in performing a direct laryngoscopy/microlaryngoscopy are as 
follows: 
STEP 1. Patient positioned supine in Boyce‘s position with head close to the head end of 
the bed. 
STEP 2. GA was induced  by the anesthesia staff. 
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Patient is intubated using a smaller sized appropriate endotracheal tube to assist the 
surgeon with more operating space.  
STEP 3. Draping of  the operative field. 
The eyes are carefully taped to prevent corneal abrasions and other injuries. The head is 
draped with sterile towels. 
STEP 4. Check for loose teeth.Insert a tooth guard  to protect the dentition.Saline soaked 
gauze piece maybe used for edentulous patients to prevent mucosal trauma to the alveolar 
ridge. 
 
STEP 5. Perform oropharyngeal examination. 
STEP 6. Continue oropharyngeal  examination. 
The  laryngoscope is gently introduced pressing into the tongue and tongue base .Suction 
is used to suction out the secretions and saliva.Structures like soft palate,uvula is 
identified and  scope advanced to visualise epiglottis. 
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STEP 7. Examination of  larynx.and hypopharynx 
Epiglottis is lifted with the tip of the scope and scope is advanced to examine 
aryepiglottic folds. The aryepiglottic folds should be followed on both sides to the 
arytenoid cartilages. The interarytenoid space should be inspected.Both pyriform sinuses 
and postcricoid region are inspected. Withdraw the scope to the epiglottis, maintaining 
the tip of the scope inferior to the tip of the epiglottis. Pressure is applied to the tongue 
base to inspect the false vocal folds and the vocal processes. Vocal folds are viewed by 
continued base of tongue pressure application.The laryngoscope is fixed using a chest 
suspension. 
STEP 8. Biopsy of the suspected laryngeal lesions is done and tissue taken separately for 
HPV study.  
Tissue is taken for biopsy using suitable miicrolaryngoscopy forceps –straight or upturn 
and separate tissue is taken from the lesion and is transferred to the VTM tubes.Tubes are 
transported to the virology lab using ice containers. 
STEP 9. Topical anesthetic is used to reduce laryngeal spasm 
STEP 10. Remove the laryngoscope and the tooth guard. 
STEP 11. Good oral suction needs to be given. 
STEP 12. Extubation by anaesthetist. 
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Sample collection:  
Sample tissue was collected  in viral transport medium and transported in an ice container 
to the virology lab.Viral transport medium is a balanced isotonic solution at physiological 
pH. It maintains the virus in the viable state.It contains fetal calf serum and antibiotics                          
Once received in lab, the samples were transferred from the VTM tube to a 1.5ml 
eppendorf tube and stored at -80
0
C until  further testing   in  -80 degree freezer 
DNA Extraction protocol: 
The DNA extraction kit used was DNeasy® Tissue kit: (Qiagen GmbH, Hilden, 
Germany).The principle of DNA extraction is column based separation. Tissues were cut 
into small pieces weighing 25mg and its digested by adding ATL buffer and Proteinase K 
at 56C.Once digested, an equal amount of AL (Lysis buffer) buffer and Ethanol were 
added. 
The DNA gets precipitated and its washed twice by adding buffers (AW1 and AW2).The 
DNA was then eluted by adding elution buffer. The extract containing the DNA  was 
stored at -20C until further testing. 
Polymerase Chain Reaction: 
The extracted DNA undergoes PCR.A known positive control was used for PCR and 
beta-globin serves as internal control.Primers used were: 
 a) PGMY 09/11: Target size: 450 basepair. 
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b) PCO4/GH20 (Beta-globin): 230 basepair 
A sample can be analyzed only if the beta globin is positive.  
Based on the presence or absence of target band (450bp), the sample was interpreted as 
positive or negative.Beta globin positive indicates that the mode of sample collection and 
whether the sample was adequate for analysis.  
Sequencing: 
If sample was positive for HPV, the amplified PCR products were purified by Millipore 
filtration and sequenced directly using an ABI Prism Big Dye terminator cycle 
sequencing ready reaction kit. 
 After a post-sequencing clean-up by Millipore filtration, the sequencing reactions were 
run on an ABI PRISM 310 genetic analyzer (PE Applied Biosystems, CA, USA).  
Finally, the data was analyzed using Bioedit software version 7.0.5.3 and study sequences 
compared to the GenBank HPV sequences. 
WHO recommended CHUV assay had to be used in case of 2 samples which were not 
able to be sequenced using routine methods. 
 PGMY-CHUV assay was developed at the RRL, Institute of Microbiology, CHUV, in 
Lausanne. It is an in-house PCR reverse blotting hybridization (RBH) assay. 
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The assay is relatively cheap (3-4$ per sample, excluding DNA extraction) given the 
hybridization membrane with covalently linked probes can be reused more than or equal 
to10 times (up to 400 samples). 
 
RESULTS 
The targeted sample size of the study was 30 cases and 30 controls .We studied a total of 
69 patients.Nine patients were excluded as the histopathological reports did not fufill the 
required criteria. 
A total of 30 controls were included in the study.They comprised vocal cord polyps,vocal 
cord nodules,vocal cord cysts and chronic laryngitis. The various types of vocal cord 
benign lesions studied were as follows: 
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Vocal cord polyps formed the major part of the control study group forming 83% of the 
controls.The other benign lesions studies were chronic laryngitis,vocal cord cysts and 
nodules. 
 
 
Sex ratio of the control population: 
 
Males comprised 87 % of the study control population.All the four female patients had  
vocal cord polyps. 
male 26
87%
females 4
13%
Sex ratio
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 Middle aged people formed most of the study group with benign lesions. 
The chief presenting complaint of all the patients in the control group was hoarseness 
though the duration was variable. Other symptoms were mild dysphagia,foreign body 
sensation throat voice fatigue and occasional odynophagia.The following table shows the 
presenting complaints pattern: 
<30 years
7%
30-60 years
83%
>60 years
10%
Age distribution
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The duration of hoarseness were variable.Majority of patients had a duration of 
hoarseness for  more than 6 months.The maximum duration was 8 years and minimum 
was of 1 month duration.  
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Majority of the patients with benign vocal cord lesions gave history of vocal misuse. 
Vocal misuse is improper voice usage such as speaking too loudly or at an abnormally 
high or low pitch. Most of them were occupation related
 
The prevalence of GERD in benign lesions were as follows: 
 
63%
37%
VOICE MISUSE
present absent
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The prevalence of smoking in benign lesions were as follows: 
 
  
PRESENT
60%
ABSENT
40%
GERD
smokers
50%
non-smokers
50%
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The prevalence of alcohol intake in the control population were as follows: 
 
Hence voice misuse was present in 63% of patients with benign lesions stressing its role   
in causing vocal cord lesions. A history of  reflux disease was also found in majority of 
patients. However smoking and alcoholism were less common among the control 
population. 
We studied 30 cases of squamous cell carcinoma of the larynx. 
All the cases studied were males. 
The commonest age group was 40-60 years. The lowest age group studied being 37 years 
and the oldest being 78 years. 
alcoholics
20%
non-alcoholics
80%
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The commonest site of origin of the lesions was supraglottis accounting to 73% of cases 
followed by glottic lesions forming 27%.There were no lesions from the subglottis as site 
of origin. 
The symptom pattern of the cancer group were as follows: 
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.The site of origin ratio was as follows:  
 
Ninety percent of the cases were chronic smokers.Alcohol consumption was prevalent in 
only 23% of cases.Alcohol intake and smoking were present in 10% of cases. 
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.The percentage of smokers were as follows: 
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Fifty percent of the cases were paan chewers 
 
GERD in laryngeal cancer patients 
 
Voice misuse in laryngeal cancers 
tobacco chewers
50%
non-tobaco 
chewers
50%
Tobacco chewing
present
33%
absent
67%
GERD
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The staging pattern of the thirty cases were as follows: 
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Moderately differentiated squamous cell carcinoma formed the majority of 
histopathological type followed by poorly differentiated and well differentiated type. 
Only three patients had carcinoma insitu type variety. 
  
HPV and laryngeal cancers 
Out of the thirty cases of squamous cell carcinomas of the larynx which were 
studied, four were positive for HPV. One was HPV 16 type and another one HPV 11 
type. Two other positive cases were not able to be sequenced probably due to low viral 
load.All the positive cases were males. All were in the age group of 40-60 years.Three 
cases were chronic smokers. Hence the percentage of positive HPV cases were:  
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10%
well differentiated
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moderately 
differentited
57%
poorly 
differentiated
23%
HPE differentiation
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None among the 4 HPV positive cases had a history of laryngeal papillomatosis in the 
past. 
Given below are the clinical details of the 4 HPV positive cases: 
Case 1: 
Hospital no.:340507f 
Age: 46 years 
Chief complaint: Hoarseness of voice since 24 months 
Other symptoms: Odynophagia and intermittent breathing difficulty and stridor 
Habits: nil 
Reflux disease: Absent 
positive
13%
negative
87%
HPV
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Voice misuse: Absent 
Nasopharyngolaryngoscopy findings: 
A mucosa covered growth seen on the right aryepiglottic fold,right arytenoid and medial 
wall of right pyriform sinus.Right hemilarynx fixed. 
Microlaryngosopy findings: 
Smooth mucosa covered friable growth involving right aryepiglottic fold, right 
arytenoids, pushing the right arytenoids medially blocking the glottis, right ventricle and 
right vocal cord involved, left vocal cord and subglottis not seen clearly. Posterior 
pharyngeal wall and bilateral pyriform sinus free of tumour, postcricoid region is free of 
tumour. 
Histopathology report: Biopsy No.38987/12: 
Moderately differentiated squamous cell carcinoma,soft tissue biopsy,supraglottis 
TNM Staging:T4aN1M0 
Stage 4 disease 
HPV Status: Positive 
HPV Type: HPV 16 type 
71 
 
Treatment received: Total laryngectomy with partial pharyngectomy with right selective 
neck dissection with right hemithyroidectomy  and  primary trachea-oesophageal 
puncture under GA  followed by adjuvant chemoradiation. 
Case 2: 
Hospital Number:124925f 
Age : 59 years 
Chief complaint: Hoarseness of voice since 4 months 
Habits: Smoking 
Reflux disease: Absent 
Voice misuse: Absent 
Nasopharyngolaryngosopy findings: 
Irregular growth involving bilateral vocal cords extending into anterior commissure. 
Bilateral vocal cords mobile 
Microlaryngoscopy findings: 
Irregular growth right false cord, right ventricle, right true cord, anterior commissure and 
left cord as well as immediate subglottis. Wedge of right false cord removed with LASER 
dissection. Type 3 LASER cordotomy done. Rest of larynx and hypopharynx normal. 
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Histopathology report: Biopsy No. 3720/12 
Poorly differentiated carcinoma, probably squamous, biopsy, right vocal cord 
TNM Staging:T2N0Mx 
Stage 2 disease 
HPV Status:Positive 
HPV type:Not able to sequence 
Treatment recieved:Radiotherapy-single modality 
Case 3 
Hospital Number:097279f 
Age:48 years 
Chief complaint: 
Hoarseness of voice and noisy breathing since 3 months 
Habits:Smoking 
Reflux disease-Absent 
Voice abuse-Absent 
Nasopharyngolaryngosopy report: 
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Proliferative growth involving entire length of left vocal cord,anterior commissure and 
anterior third of right vocal cord with subglottic extension. 
Microlaryngoscopy findings: 
Proliferative growth involving entire length of left vocal cord,anterior commissure and 
anterior third of right vocal cord, subglottis on both left and right side and 
anteriorly..Growth extends to left ventricle.Left ventricular band edematous.Right 
ventricular band,bilateral arytenoids,bilateral pyriform sinus and postcicoid region 
normal. 
Histopathology report:Biopsy No.40837/11 
Squamous cell carcinoma-moderately differentiated ,biopsy tissue from bilateral vocal 
cords. 
TNM Staging:T3N0Mx 
Stage 3 disease 
HPV status: Positive 
HPV Type: Not able to sequence 
Treatment received: Radiotherapy 
Case 4 
Hospital Number:130857f 
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Age:62 years 
Chief complaint:Hoarseness of voice since 6 months 
Habits:Smoking 
Voice misuse:Absent 
Reflux disease:Absent 
Nasopharyngolaryngoscopy report: 
Growth involving entire length of right vocal cord upto anterior commissure.Malignancy 
glottis. 
Microlaryngosopy findings: 
Proliferative growth involving entire length of right vocal cord upto the anterior 
commissure.Anterior commissure,left vocal cord,right false cord,rest of larynx and 
hypopharynx,subglottis free of tumour. 
Histopathology report:Biopsy No-5359/12 
Well differentiated squamous cell carcinoma,right vocal cord,separately sent superior 
resection margin,free of tumour. 
TNM Staging:T1aN0Mx 
Stage 1 disease 
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 HPV status:Positive 
HPV type: HPV 11 
Treatment received:Transoral LASER microsurgery and excision under GA 
Statistical analysis 
The etiological factors of  laryngeal cancers studied were smoking, alcoholism, tobacco 
chewing ,laryngopharyngeal reflux and HPV.The role of HPV in laryngeal cancer was 
studied in detail.The role of each etiological factor was studied separately.Only smoking 
and tobacco chewing showed statistically significant association  in causing laryngeal 
cancer with a p value of 0.010 and 0.012 respectively.The results of HPV in laryngeal 
cancers were statistically insignificant with a p value of 0.121.The statistical results were 
as follows: 
Univariate risk 
 Case n (%) Control n(%) p value 
Smoking 26 16 0.010 
Alcoholism 7 6 0.750 
Tobacco chewing 15 6 0.012 
Reflux disease 9 15 0.187 
Voice misuse 10 18 0.069 
HPV 4 0 0.121 
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 p value Odds ratio 
SMOKING 0.010 5.804 
TOBACCO  CHEWING 0.012 5.296 
 
Statistical analysis showed significant association of smoking and tobacco chewing with 
laryngeal cancers.While smoking had an association p value of 0.010,tobacco chewing 
had a p value of 0.012.Results showed that 5 times increased risk of getting laryngeal 
cancers compared to non-smokers.It also showed that tobacco chewers had a 5 times 
increased risk compared with non tobacco chewers. 
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DISCUSSION 
Laryngeal cancer is the most common head and neck cancer worldwide
94
.It is important 
to study the various etiological factors causing laryngeal cancers because carcinogenesis 
can be prevented by controlling these factors. Various studies conducted in different parts 
of the world ascertain the fact that tobacco is a definitive causative agent for laryngeal 
cancer
21
.Among tobacco users, smoking is the habit which has been shown to have 
maximum carcinogenic effect followed by tobacco chewing.
22
  Alcohol also has a 
significant part in laryngeal carcinogenesis
20
.Smoking and alcohol consumption appear to 
have a synergestic action compared to each of them alone.The morbidity and the 
mortality caused by laryngeal cancers is significant  in that  surgery and radiation therapy 
can cause disabilities in speech and swallowing affecting the individual as well as the 
family.The burden of laryngeal cancer can be brought down by understanding the various 
etiological agents in detail.The search for other causes other than habits of tobacco use 
and alcohol consumption is likely to be useful in the  prevention of laryngeal cancers. 
Traditionally,middle aged males who were chronic smokers or alcoholics were thought to 
be more prone to oropharyngeal and  laryngeal cancers.However recent trends show a 
group of  oropharyngeal  cancer patients who were non-smokers and non-alcoholics and 
were from a younger age group with HPV positive status.Studies reveal that these patients 
seem to respond better to chemoradiation and have a better prognosis
68
.Though HPV 16 
screening is not mandatory  at  present ,it is expected to be made mandatory in the future 
for cases of oropharyngeal cancers as it is recommended by most cancer treatment 
guidelines. Hence it is important to study the HPV status of cancer patients so that these 
patients can be treated as a separate category since  they respond better to treatment.The 
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outcome of treatment can be better predicted in these patients and  the management  plan 
can be modulated. 
Newer studies are aimed at finding out the role of Human papilloma viruses in 
carcinogenesis and their impact on treatment outcome.It is now well established that HPV 
has a significant role in cervical and oropharyngeal cancers. Our study was aimed at 
studying prevalence of HPV in laryngeal cancers presenting to a tertiary Hospital during 
the period November 2011 to July 2013 .We studied 30 cases of histopathology proven  
laryngeal cancers and 30 patients with benign vocal cord lesions as disease controls. All 
30 cases were squamous cell carcinomas of the larynx. 
Laryngeal cancer is most common in middle aged men and our study also showed similar 
results
84
. All our cancer group patients were men. Nineteen patients out of thirty were in 
the age group of 40-60 years. Only 2 were below 40 years and 9 were in the age group of 
above 60 years. The increased prevalence of laryngeal cancer in the middle age group is 
attributable to the habit pattern of individuals. Most of them start the habits of smoking 
and alcohol intake at about  2
nd
 to 3
rd
 decades of life. Hence by the age of  40 years most 
of them would have crossed 20 pack years. Studies have shown that as the number of 
pack years increases the relative risk for carcinogenesis also increases
85
.  
Hoarseness of voice was the predominant symptom in the both the cancer group as well 
as the control group. Whereas 27 cancer patients presented with hoarseness as the chief 
symptom, all the 30 control patients all had hoarseness as the chief complaint. Other 
studies showed that the most common site for laryngeal squamous cell carcinoma is the 
glottic larynx
86
.However in our study, the majority of the lesions were from the 
supraglottis accounting to 73%.Eventhough supraglottic lesions formed the majority, the 
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chief complaint of hoarseness in the cancer group in our study could be explained by the 
spread of the disease to the glottis. The duration of symptoms in the cancer group were 
less than 6 months in 22 patients ie 73 %.In the control group the duration of hoarseness 
was mostly more than 6 months. 
Our study also confirmed the significant role of smoking as an etiological factor in 
laryngeal cancers. Twenty  six out of thirty patients were smokers. However only 23% of 
the cancer group gave history of alcohol intake and it did not show significant role in 
causing laryngeal cancers in our study. Our study included patients from different 
conservative religious backgrounds where habits such as alcohol intake are prohibited. 
This maybe the reason why our study did not find alcohol intake as a major risk factor. 
Tobacco chewing also proved to be an important risk factor in accordance with the 
literature. The association was found to be significant with a p value of 0.012.Our study 
showed that both smoking and tobacco chewing had 5 times increased risk of acquiring 
laryngeal cancers. The control group showed less patients with habits such as alcohol 
consumption and smoking. Only half of them were smokers and only 20% gave history of 
alcohol intake. Voice misuse was found in 63% of the control patients in our study 
whereas it was present in only 33% cancer group patients. This reinfores the role of voice 
misuse in vocal cord benign lesions. 
The role of gastroesophageal reflux disease as a risk factor for laryngeal cancers has been 
studied in recent years. Some studies had shown increased risk compared to non-cancer 
group. However in our study, the association between GERD and laryngeal cancers was 
not statistically  significant. It was present in only 33% of cancer patients whereas 60% of 
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the control group had symptoms suggestive of GERD.As per clinical evaluation, our 
study showed increased prevalence of GERD in the benign laryngeal lesions. 
Histopathologically, moderately differentiated squamous cell carcinoma was the 
commonest variety followed by poorly differentiated and well differentiated variety. 
Among the four HPV positive cases also, 2 were moderately differentiated. The 
maximum number of cases were in stage 2 according to TNM classification followed by 
stage 3 and stage 4. 
In our study group four cancer cases(13%) were positive for HPV among the 30 cases 
studied. None among the 30 control patients were positive for HPV. Baumann etal 
studied 38 carcinoma insitu or T1 lesions glottis and had  6 (16%)positive cases.In an 
Indian study by Jacob etal,15 cases were positive among the 44 cases of  laryngeal 
cancers studied. In our study all the HPV positive patients were males and all of them 
were in the middle age group. One of them was HPV 16 type and another one HPV 11 
type whereas two positive samples were not able to be sequenced. In a metaanalysis by Li 
etal,9 studies from the Asian subcontinent gave a prevalence of 25%
1
.However our study 
showed decreased prevalence of HPV in laryngeal cancers and statistics showed  the 
relationship to be insignificant(p value=0.121). 
The patient positive for HPV 16 did not have any habits such as tobacco use or 
alcoholism. He did not have a history of reflux disease as well. As other common risk 
factors were absent in this patient it could  be  concluded that HPV was the causative 
agent for his disease.   Other HPV positive cases were chronic smokers. However as 2 
among them were not sequenced,it could not be serologically confirmed whether it was 
high risk or low risk  HPV genotype. These two samples could not be  sequenced despite 
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being tested by an alternate method, namely the PGMY CHUV assay
102
. The reason for  
this could be low HPV copy numbers that were not sufficient to be sequenced or typed. 
The successful sequencing would have given us  a clearer picture of the genotype and 
hence the carcinogenicity. 
HPV 11 is known to cause laryngeal papillomatosis.
63
The case positive for HPV 11 in our 
study had a well differentiated squamous cell carcinoma of the glottis in stage 1.Two 
among the 4 HPV cases were moderately differentiated squamous cell carcinomas  
histopathologically.The other two cases were well differentiated and another poorly 
differentiated, respecively. Among four positive cases, one each was in 1,2,3 and 4 
stages. 
There were some limitations in the study .The problem faced during the data collection 
was the collection of detailed sexual history of the patients.As the patients were from 
different conservative religious,cultural and social backgrounds they   were reluctant and 
refused to answer questions related to their personal sexual history. Most of the patients 
were accompanied by one or two family members at all times and it was difficult to take 
detailed sexual history in their presence in an outpatient clinic setting. Another drawback 
was the inability to sequence the  2 HPV positive cases.The reasons for this have been 
described earlier. 
In a meta analysis by Li X
1
 et al including 55 eligible studies,the overall  prevalence of 
HPV in laryngeal cancer tissues was 28%. High risk genotype HPV-16 was most 
frequently observed type, with a prevalence of 19.8%. High risk HPV type infection was 
detected in a total of 26.6% laryngeal cancer patients.The meta-analysis based on 12 
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eligible case-control studies suggests a strong association between HPV infection and 
laryngeal squamous cell carcinoma, with a summary odds ratio (OR) of 5.39. 
The relation between HPV and cancer larynx has to be studied further  to include a larger 
series of patients and to follow up the HPV positive cases long term to understand better 
the role of HPV infection in the treatment outcome and prognosis.HPV detection in 
normal laryngeal tissues has not been standardised and hence the general prevalence has 
not been determined
57
. It is important to study whether HPV is merely a ―by-stander 
infection‖ or  a ―latent infection‖ in causing laryngeal cancers or whether it has a 
definitive carcinogenic role and whether it has a significant effect on the prognosis and 
treatment outcome of laryngeal cancers. 
The development of vaccines against cervical cancers has had a significant impact in the 
management and prognosis of cervical cancers.In current times it has been postulated that 
this maybe soon applicable for oropharyngeal cancers. Further studies will be needed to 
see whether these can be translated to the management of laryngeal cancers.However the 
fact that no single HPV genotype have been identified in laryngeal cancers compared to 
HPV 16 in oroparyngeal cancers,is a limitation for translation of vaccines. At the current 
time the results of studies have been variable and the effect of HPV on the treatment 
outcome and prognosis of laryngeal cancers has yet to be comprehensively studied 
.Further studies are required before any changes in management are implemented in 
national treatment policies and laryngeal cancer management guidelines .  
The role of  HPV in laryngeal cancers need to be confirmed by detailed studies including 
larger group with long term followup . Health education regarding the etiology of HPV 
infection ie sexual transmission and the need for safe sex needs to be emphasised.  
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CONCLUSION 
The role of Human papilloma virus in head and neck carcinogenesis is well established. 
Studies have already shown a significant association between HPV and oropharyngeal 
cancers
73
 with HPV 16 causing more than 90% of cases.
5
However its role in laryngeal 
cancers is yet to be clearly established.The treatment outcome of  cases with HPV related 
laryngeal cancers is still being currently studied . 
There is significant paucity of  case-control studies in literature  that have  looked at HPV 
and laryngeal cancers in the Asian subcontinent.We studied 30 cases of 
histopathologically proven  laryngeal squamous cell carcinomas as  cases and benign 
lesions of larynx such as vocal cord polyps,nodules or cysts  as disease controls  .           
There were 4 positive cases of HPV in the laryngeal cancer group(13%) whereas there 
were no positive cases in the control group. This shows an  increasing trend towards 
positivity in the case group compared to the control group. However the association 
between HPV and laryngeal cancers was found to be statistically insignificant (p 
value=1.21).  One of the cases  was  genotyped as high risk HPV type 16 and another  
was HPV 11.The other two  positive cases could not be sequenced even after using WHO 
recommended CHUV assay.  
Our study also showed a significant association between tobacco chewing and laryngeal 
cancers in addition to smoking.This is in accordance with existing studies which have 
shown a similar correlation. 
84 
 
The technical limitation in sequencing positive HPV samples were a drawback for our 
study.Other limitation was the  small sample size.The data collection in the form of 
detailed sexual history was another major drawback. 
HPV subtyping needs to be done for all juvenile and adult-onset laryngeal papillomatosis 
in view of  chances of malignant transformation.These patients need to be followed up 
regularly. HPV testing is strongly recommended in the workup of laryngeal cancer 
patients especially in the younger age groups without any co-existing risk habits such as 
smoking ,tobacco chewing and alcohol consumption. Further studies should be conducted 
including a larger group of patients to confirm the role of HPV in laryngeal cancers and to 
followup these patients to study the treatment response and survival .This can open new 
dimensions in the treatment and prognosis of laryngeal cancers. 
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INFORMED  VALID CONSENT 
Study number- 
Participant‘s name- 
Date of birth/age                                                   
I, son/daughter/wife of has been explained in my own understandable language about the 
proposed study.I have been explained about the study which involves taking tissue from 
the lesion for PCR analysis during direct/microlaryngoscopic biopsy under GA which is 
done routinely for patients with my disease(clinically diagnosed laryngeal cancers/vocal 
cord polyp).I have been explained that there is no additional risk in the study.It has been 
explained to me that I am free to withdraw from the study any time I want and will not in 
any way compromise the treatment ,the ENT department is giving me.I understand that 
my identity and participation will not be revealed in any information  released to third 
parties.I am giving this consent on my own free will.I have been explained about the 
study in a language familiar to me.I hereby give my full valid consent for the proposed 
study 
Name                                           Signature                                                  Doctor 
Name of relative(guardian/parent)                
Signature 
Name of witness 
Signature 
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PATIENT INFORMATION SHEET 
I will be part of this study.As part of the study,I will be asked details about my disease. 
This study is aimed at finding out the prevalence of a virus named Human Papilloma 
Virus in cancer of the larynx and vocal cord polyps.I am clinically diagnosed with cancer 
of the voicebox/ vocal cord polyp.A test(biopsy)should be routinely done in which tissue 
is taken to test for features of cancer.A microscope assisted visualisation of the voicebox 
is done and tissue is taken for biopsy under general anaesthesia after taking written valid 
consent.This is done routinely  for all patients with a similar diagnosis.During the process 
of taking tissue for biopsy,some extra tissue will be taken for this study.Tissue will be 
sent for a test called PCR analysis.There wont be any other risks involved in this study.I 
need not pay any extra money for the test.This study can help in studying the cause of 
laryngeal cancers. I can withdraw from the study at any moment if you feel so and that in 
no way will compromise my treatment at ENT department.My participation in the study 
will remain confidential and shall be known only to the investigators.For any queries I 
can contact: 
Dr.Philip George 
PG Registrar 
CMC Vellore 
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PROFORMA 
                         HUMAN PAPILLOMA VIRUS IN LARYNGEAL CANCERS 
Serial No.:  
Name:  
Age:  
Sex:  
Hospital number:  
Date of Admission:  
Unit:  
Chief complaint: 
Other complaints: 
Duration of symptoms:  
Voice misuse: 
GERD: 
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Habits:  
Any previous treatment taken:  
(surgery/ chemotherapy/ radiotherapy)   
NPL scopy findings:  
Surgery date:  
Surgeons: 
Microlaryngoscopy findings:  
Biopsy no. and date:  
Biopsy report:  
Final Diagnosis: 
HPV report: 
HPV type: 
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ML SCOPY OR SETTING 
 
 
VTM TUBES 
 
 
 
  
EPPENDORF TUBE 
 
 
-80 DEGREE FREEZER 
 
  
BIOSAFETY CABINET FOR DNA EXTRACTION 
 
 
EXRACTION OF HPV DNA: DNeasy® Tissue kit 
  
THERMAL CYCLER 
 
SEQUENCER  
serial sex age hoarseness                                                              dysphagia  odynophagia other duration smoking aloholism tobacco other1 gerd voice
1 1 58 2 1 1 1 5 1 2 1 2 1 2
2 1 76 1 2 2 1 2 1 1 2 2 2 2
3 1 53 1 2 2 2 4 1 2 1 2 2 1
4 1 46 1 2 1 1 24 2 2 2 2 2 2
5 1 65 1 2 2 2 12 2 2 1 1 1 1
6 1 63 1 2 1 1 4 1 2 1 2 2 1
7 1 60 2 2 2 1 3 1 2 1 2 2 2
8 1 47 1 2 1 2 5 2 2 1 2 2 1
9 1 56 1 2 2 2 4 2 2 1 2 2 2
10 1 59 1 1 1 1 2 1 2 1 2 2 2
11 1 57 1 2 2 2 12 1 2 2 2 2 2
12 1 54 1 2 2 2 24 1 2 2 2 2 1
13 1 58 1 2 2 2 8 1 2 1 2 1 2
14 1 57 1 2 2 1 1 1 1 2 2 1 2
15 1 55 1 2 2 2 12 2 2 2 2 1 1
16 1 78 1 1 1 2 1 1 2 2 2 2 2
17 1 45 2 1 1 2 2 1 2 2 2 1 2
18 1 59 1 2 2 2 4 1 2 2 2 2 2
19 1 48 1 2 2 1 3 1 2 2 2 2 2
20 1 60 1 2 2 2 6 1 2 2 2 2 1
21 1 57 1 1 1 2 5 1 2 1 2 2 2
22 1 55 1 2 2 1 72 1 1 1 2 2 2
23 1 38 1 2 2 1 12 1 1 1 2 2 1
24 1 61 1 2 2 2 10 1 1 2 2 1 2
25 1 71 1 2 2 2 2 1 2 2 2 2 2
26 1 65 1 2 1 1 2 1 1 2 2 2 2
27 1 71 1 2 2 1 2 1 2 2 2 1 2
28 1 37 1 2 2 2 3 1 2 1 2 1 1
29 1 59 1 2 2 2 3 1 2 1 2 2 1
30 1 64 1 2 2 2 2 1 1 1 1 2 2
serial sex age hoarseness                                                              dysphagia  odynophagia other duration smoking aloholism tobacco other1 gerd voice
1 2 42 1 2 2 2 4 2 2 1 2 1 1
2 1 56 1 2 2 2 6 1 2 1 2 1 1
3 1 58 1 2 1 1 6 2 2 2 2 2 1
4 1 32 1 2 2 2 7 1 1 2 2 2 1
5 2 47 1 2 2 1 4 2 2 2 2 1 1
6 1 27 1 1 2 2 24 1 1 2 2 2 1
7 1 47 1 2 2 2 1 1 1 2 2 1 1
8 1 62 1 2 2 2 3 1 2 2 2 2 2
9 2 57 1 2 2 1 2 2 2 2 2 1 1
10 1 46 1 2 2 2 6 1 2 2 2 1 2
11 1 26 1 2 2 2 60 1 2 2 2 1 1
12 1 60 1 2 2 2 8 1 2 2 2 1 1
13 2 35 1 2 2 1 8 2 2 2 2 1 2
14 1 35 1 2 2 2 6 2 2 2 2 2 2
15 1 39 1 2 2 2 9 2 2 2 2 2 1
16 1 36 1 2 2 2 12 2 2 2 2 1 1
17 1 50 1 2 2 2 23 1 2 2 2 1 1
18 1 49 1 2 2 2 12 1 2 2 2 1 2
19 1 49 1 2 2 2 12 1 2 2 2 2 1
20 1 58 1 2 2 2 24 2 2 2 2 2 2
21 1 47 1 1 2 2 6 2 1 1 2 2 2
22 1 45 1 2 2 2 6 2 2 1 2 1 1
23 2 3 1 2 2 2 8 1 1 2 2 2 1
24 1 37 1 2 2 1 96 1 2 2 2 2 2
25 1 33 1 2 2 1 36 1 1 1 2 2 2
26 1 25 1 2 2 2 36 2 2 2 2 1 2
27 1 37 1 2 2 2 4 1 2 2 2 2 2
28 1 62 1 2 2 1 2 1 2 2 2 2 2
29 1 42 1 2 2 2 72 2 2 1 2 1 1
30 1 54 1 2 2 2 12 2 2 2 2 2 1
serial npl date ml site who histopatho tnm staging hpv
1 Malignancy glottis T3 2/25/2013 Ulceroprolif growth left vc false cord 2 1 3 T3NOMX 3 0
2 Malignanacy glottis with lesion hypopharynx 6/12/2013 growth left false cords ventricle r hpx 2 1 4 T3NOM0 3 0
3 Malignancy glottis 6/6/2013 prolif lesion right vc with antr commisu 2 1 2 T1N0MX 1 0
4 Malignancy supraglottis 11/14/2013 right aef arytenoids pushing right aryte 1 1 3 T4N1M0 4 1
5 Right vc polyp 7/9/2013 polyp anterior one third right vc 2 1 TisN0MX 0
6 Malignancy glottis 4/15/2013 growth anterior half of bilateral vcs 2 1 4 T4N0M0 4 0
7 Malignancy supraglottis 1/30/2013 up growth left epiglottis AEF arytenoid 1 1 3 T2N0MX 2 0
8 Malignancy glottis 1/18/2013 growth left vc,right true cord subglotti 2 1 3 T4N0M0 4 0
9 Malignancy glottis 2/4/2013 growth middle 1/3 right vc antr commisur 2 1 3 T3N0MX 3 0
10 Malignancy supraglottis 1/15/2013 1 1 3 T2NOMO 2 0
11 Malignancy glottis 6/26/2013 growth rt false cord,ventricle true vc 2 1 3 T3N2MX 4 0
12 Malignancy glottis 7/27/2013 growth rt true vc false vc AEF 2 1 3 T3N0MX 3 0
13 Malignancy glottis 6/7/2013 growth rt vc ant commissure ant 2/3 lt v 2 1 4 T2N0M0 2 0
14 Malignancy glottis 3/19/2013 irregularity left vc antr commisure 2 1 4 T2N0MX 2 0
15 Growth left vc 4/9/2012 thickened antr 2/3 left vc with keratoso 2 1 TisNOM 0
16 Malignancy supraglottis 12/5/2011 growth rt false cord,aef,arytenoid,true 1 1 3 T3N0MX 3 0
17 Malignancy supraglottis 1/16/2013 growth left arytenoid aef pfs,rt aryteno 1 1 4 T4N1M0 4 0
18 Malignancy glottis 2/2/2012 growth rt true cord false cord ventricle 2 1 4 T2N0MX 2 1
19 Malignancy glottis 12/19/2011 growth left vc antr comm.antr 1/3 rt vc 2 1 3 T3NOMX 3 1
20 malignancy glottis 2/16/2012 Growth rt vc antr comm lft vc 2 1 2 T1N0MX 1 1
21 Malignancy glottis 3/8/2012 growth left true false cord AEF ventricl 2 1 TisN0M 0
22 Malignancy supraglottis 5/7/2012 growth rt AEF False cord pfs ventriclevc 1 1 4 T3N0MX 3 0
23 Malignancy glottis 5/7/2012 growth entire left vc 2 1 3 T2N0Mx 2 0
24 Malignancy glottis 4/25/2012 ulcerative growth antr 2/3 rt vc 2 1 3 T2N0Mx 2 0
25 Malignancy glottis 4/22/2012 irregularity b/l vcs 2 1 2 T2N0MX 2 0
26 Growth left aef arytenoid pfs righ pfs postcricoid 7/6/2013 1 1 3 T3N1Mx 3 0
27 Malignancy glottis 7/12/2013 exophyti growth left vc to subglottis 2 1 3 T3N0MX 3 0
28 Malignany supraglottis 7/19/2013 malignancy supraglottis 1 3 T3N2CMx 4 0
29 Malignancy glottis 7/16/2013 irregular firm lesion right vc 2 1 3 T2N0MX 2 0
30 malignancy glottis 7/23/2013 proliferative growth entire length true cord antr comm 2 3 T3NOMX 3 0
serial npl date ml site who histopatho tnm staging hpv
1 Right vc polyp 7/12/2013 broad based polyp rt junction 1/3-2/3 2 5 0
2 Left vc polyp 7/8/2013 broad based polyp left vcjunction1/3-2/3 2 5 0
3 Right vc polyp 7/8/2013 pinkish right v polyp at junction 2 5 0
4 Right vc polyp 6/18/2013 mid third right vc 2nd polyp antr commis 2 5 0
5 Right vc polyp 7/2/2013 bulge right vc junction of antr 1/3  2/3 2 7 0
6 Left vc polyp 7/2/2013 trilobed polyp anterior 1/3 left vc 2 5 0
7 gerd o r/o malignancy 7/2/2013 congested vcs with mild irregularity 2 7 0
8 Right vc polyp 7/14/2013 broad based polyp right vc 2 5 0
9 Right vc polyp 7/31/2012 polyp junction of ant 1/3 & post 2/3 rt 2 5 0
10 Left vc polyp 12/19/2011 broad based polyp left vc 2 5 0
11 Right vc olyp 1/25/2012 large bilobed right vc polyp at junction 2 5 0
12 Irregula medial surface b/l vcs 1/25/2012 irregular mrgins b/l vcs 2 7 0
13 Left hemorrhagi polyp 6/14/2013 polyp junction 1/3 &2/3 left vc 2 5 0
14 Right vc polyp 6/18/2013 broad based polyp right vc 2 5 0
15 Right v polyp 6/4/2013 right vc polyp antr 1/3rd 2 5 0
16 Right vc polyp 6/5/2013 cyst medial margin right vc 2 5 0
17 Polyp antr 1/3 postr 2/3 left vc 5/6/2013 polyp junction antr 1/3 postr2/3 left vc 2 5 0
18 Left vc polyp 4/15/2013 left vc polyp at 1/3-2/3 junction 2 5 0
19 Right vc polyp 1/23/2013 right vc polyp 1/3-2/3 junction 2 5 0
20 Right vc polyp 1/24/2013 right vc polyp antr 1/3-2/3 junction 2 5 0
21 Growth left vc 11/2/2012 right vc polyp antr 1/3 keratosis lft vc 2 5 0
22 ?left intracordal cyst 1/23/2013 intracordal cyst left vc 2 6 0
23 Right vc polyp 12/18/2012 polyp anterior 1/3 right vc 2 5 0
24 Left vc cyst 1/22/2013 polyp anterior 1/3 left vc 2 5 0
25 Right vc polyp 2/7/2013 anterior 1/3 right vc polyp 2 5 0
26 right vc polyp 7/13/2012 Polyp anterior 1/3-2/3 junction rt vc 2 5 0
27 Right vc polyp 6/14/2013 polyp superior surface right vc 2 5 0
28 Left vc lesion vallecular cyst 7/4/2013 polypoidalesion antr comm 1/3 left vc 2 8 0
29 nil 6/15/2013 polypoidal growth medial surface lt vc 2 5 0
30 Left vc polp/polypoidal lesion 7/10/2013 Polypoidal lesion antr 1/3 left vc 2 5 0
 
 
